Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Derek Einhorn

Internal Medicine Novi, MI Medical Doctor

NPI 1801855762 CMS profile 35943

39475 Lewis Drive, Suite 130, Novi, MI 48377

Open in the dashboard

General payments

$5,954

352 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derek Einhorn of Novi, MI is reported in the CMS Open Payments database as having received $5,954 across 352 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,571 89
2024 General $1,401 79
2023 General $984 66
2022 General $1,005 57
2021 General $365 22
2020 General $324 19
2019 General $304 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Einhorn
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Derek Einhorn were reported at $1,571. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Derek Einhorn Internal Medicine median Middle half National median
2019 $304 $159 $48–$570 $163
2020 $324 $119 $33–$402 $114
2021 $365 $135 $37–$521 $132
2022 $1,005 $141 $42–$496 $149
2023 $984 $149 $45–$519 $160
2024 $1,401 $154 $47–$537 $164
2025 $1,571 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $884 69 payments
  2. AbbVie, Inc. $882 40 payments
  3. Novo Nordisk Inc $798 47 payments
  4. Pfizer Inc. $508 31 payments
  5. AstraZeneca Pharmaceuticals LP $298 20 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $257 14 payments
  7. Exact Sciences Corporation $217 11 payments
  8. Amgen Inc. $204 13 payments
  9. GlaxoSmithKline, LLC. $198 10 payments
  10. Abbott Laboratories $191 9 payments
  11. Other $1,518 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,940 351 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $619 36 payments
  2. MOUNJARO $509 37 payments
  3. RYBELSUS $491 29 payments
  4. UBRELVY $479 18 payments
  5. ZEPBOUND $349 25 payments
  6. QULIPTA $340 19 payments
  7. JARDIANCE $311 29 payments
  8. COMIRNATY $235 14 payments
  9. NURTEC ODT $196 14 payments
  10. PREVNAR 20 $187 11 payments
  11. Other $5,113 303 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

3,051

Median for Internal Medicine: 777

Drug cost

$389,590

Median for Internal Medicine: $73,373

Branded share of claims

24.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 117 $162,903
Ozempic Semaglutide Brand 62 $93,337
Jardiance Empagliflozin Brand 38 $41,956
Eliquis Apixaban Brand 24 $28,407
Farxiga Dapagliflozin Propanediol Brand 15 $16,605
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 38 $8,388
Paxlovid Nirmatrelvir/Ritonavir Brand 17 $2,859
Atorvastatin Calcium Generic 245 $2,508
Losartan Potassium Generic 149 $1,917
Rosuvastatin Calcium Generic 100 $1,678

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$58,280

Of which drugs: $4,714

Medicare patients

183

Average age 72

Services billed

3,724

95 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 37%
Ischemic heart disease 27%
Diabetes 26%
Chronic kidney disease 26%
Depression 23%
Atrial fibrillation 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 21 21 $1,708

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $103
$103 — —
UBRELVY
  • AbbVie, Inc. $98
$98 — —
MOUNJARO
  • Lilly USA, LLC $93
$93 117 —
JARDIANCE
  • Lilly USA, LLC $56
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$74 38 —
QULIPTA
  • AbbVie, Inc. $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record